| # | % | |||||
|---|---|---|---|---|---|---|
| 51 | ARIAD PHARMACEUTICALS ORD (NMS) | 1,200,000 | 7,644,000 | 0.62% | ||
| 52 | Intra-Cellular Therapies, Inc. | 200,000 | 3,372,000 | 0.27% | ||
| 53 | VISTEON CORP COM NEW | 30,000 | 2,910,000 | 0.24% | ||
| 54 | ROYCE VALUE TR INC | 179,184 | 2,867,000 | 0.23% | ||
| 55 | REPROS THERAPEUTICS INC | 145,891 | 2,524,000 | 0.21% | ||
| 56 | ADAMS DIVERSIFIED EQUITY FD | 155,104 | 2,133,000 | 0.17% | ||
| 57 | Idenix Pharmaceuticals Inc | 61,369 | 1,479,000 | 0.12% |
Portfolio data is normalized using SEC Form 13F filings, including the Original 13F-HR (0000040417-14-000170, filed 2014.08.01).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
